# Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

> **NCT05982795** · — · RECRUITING · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **OTHER:** Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge
- **OTHER:** Olfactory Function Testing
- **OTHER:** Survey Completion

## Key facts

- **NCT ID:** NCT05982795
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-08
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982795, "Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05982795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*